CVS Health Corporation (CVS)
NYSE: CVS · Real-Time Price · USD
70.26
-3.52 (-4.77%)
At close: Sep 8, 2025, 4:00 PM
70.19
-0.07 (-0.10%)
After-hours: Sep 8, 2025, 6:03 PM EDT
CVS Health Revenue
CVS Health had revenue of $98.43B in the quarter ending June 30, 2025, with 8.35% growth. This brings the company's revenue in the last twelve months to $384.33B, up 6.21% year-over-year. In the year 2024, CVS Health had annual revenue of $370.66B with 3.93% growth.
Revenue (ttm)
$384.33B
Revenue Growth
+6.21%
P/S Ratio
0.24
Revenue / Employee
$1,281,097
Employees
300,000
Market Cap
89.11B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 370.66B | 14.03B | 3.93% |
Dec 31, 2023 | 356.62B | 34.99B | 10.88% |
Dec 31, 2022 | 321.63B | 30.72B | 10.56% |
Dec 31, 2021 | 290.91B | 23.00B | 8.59% |
Dec 31, 2020 | 267.91B | 12.14B | 4.75% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
CVS News
- 5 days ago - Updated flu vaccinations now available at CVS Pharmacy® and MinuteClinic® - PRNewsWire
- 7 days ago - Top 10 High-Yield Dividend Stocks For September 2025 - Seeking Alpha
- 13 days ago - Jim Cramer says CVS stock is a buy at these levels. Here's why - CNBC
- 18 days ago - CVS Health Declines To Add Gilead's Steeply Priced New HIV Prevention Drug To Its Plans - Benzinga
- 19 days ago - Exclusive: CVS holds off adding Gilead's new HIV prevention shot to drug coverage lists - Reuters
- 19 days ago - CVS unit must pay $290 million in drug whistleblower lawsuit, judge rules - Reuters
- 21 days ago - CVS cannot obtain AIG, Chubb opioid coverage, top Delaware court rules - Reuters
- 21 days ago - CVS Health: Outlier In Healthcare Implosion - Further Margin Recovery Ahead - Seeking Alpha